Using advanced proteogenomic technologies to look at genetic makeup and proteins, researchers from the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) in America have identified four subtypes of clear cell renal cell carcinoma (RCC).
The researchers found that almost all of the clear cell RCC tumour samples in the study lacked chromosome 3p. They identified this as an apparent hallmark of clear cell RCC.
In addition, the researchers identified four distinct immune-based subtypes of clear cell RCC based on their immune cell differences. These differences could potentially be used to help predict overall survival and response to treatment with VEGF inhibitors and immunotherapy. The information could also be used to help researchers identify potential molecular targets for the development of new drugs.
Read more in John Hopkins Medicine here